Sodium phosphate


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Hypophosphataemia ≤100 mmol of phosphate/day. IV Severe hypophosphataemia As monobasic potassium phosphate: ≤9 mmol of phosphate, repeat 12 hrly if needed. Rectal Mild osmotic laxative for bowel evacuation and cleansing Soln containing monobasic and dibasic sodium phosphates in various compositions. Use as directed.
Dosage Details
Intravenous
Severe hypophosphataemia
Adult: As monobasic potassium phosphate: Up to 9 mmol of phosphate given over 12 hours, repeat every 12 hours if needed. Alternatively, 0.2-0.5 mmol/kg phosphate (max: 50 mmol) may be given over 6-12 hours.

Oral
Hypophosphataemia
Adult: Up to 100 mmol of phosphate daily.

Rectal
Mild osmotic laxative for bowel evacuation and cleansing
Adult: Usually contains monobasic and dibasic sodium phosphates but the composition and dosage may vary. Phosphate enemas work within 2-5 minutes. Use as directed.
Renal Impairment
Oral:
Dose reduction may be necessary.
Rectal:
Dose reduction may be necessary.
Incompatibility
Oral:
Incompatible with calcium salts.
Rectal:
Incompatible with calcium salts.
Contraindications
Severe renal function, congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon or hypomotility syndrome, hypertension, hyperkalaemia, oedema, low serum-calcium concentrations, infected phosphate renal calculi.
Special Precautions
Chronic renal disease, pre-existing electrolyte disturbances. Concurrent admin with drugs that may affect electrolyte levels. Correct electrolyte abnormalities before initiating therapy. Monitor renal function, serum calcium, serum phosphorus, serum potassium, and serum sodium at periodic intervals during therapy. Caution in patients taking drugs that may prolong QT interval. Ensure adequate hydration. Pregnancy. Elderly or debilitated patients.
Adverse Reactions
Abdominal discomfort or pain, diarrhoea, nausea, vomiting, hypernatraemia, dehydration (with high doses). Convulsions, drowsiness, mood change, trembling, malaise, loss of appetite, muscle spasm (with long-term use). Less frequently, headaches, dizziness, mental confusion, seizures, weakness or heaviness of legs, muscle cramps, numbness, tingling, pain, arrhythmia; shortness of breath or troubled breathing; swelling of lower legs or feet; unusual weight gain, low urine output; unusual thirst; bone and joint pain.
Overdosage
May lead to severe electrolyte disturbances, including hyperphosphataemia, hypocalcaemia, hypernatraemia, or hypokalaemia, as well as dehydration and hypovolaemia. May also lead to cardiac arrhythmias, seizure, renal failure and death. Monitor carefully and treat symptomatically until stable.
Drug Interactions
Concurrent use with aluminium, calcium, or magnesium salts will reduce absorption of phosphates. Vitamin D increases the GI absorption of phosphates and risk of hyperphosphataemia. Increased risk of hyperphosphataemia, hypocalcaemia, and hypernatraemia when used in patients receiving diuretics or drugs that may affect serum electrolytes. Increased risk of ectopic calcification when used concurrently with calcium supplements or calcium-containing antacids.
Food Interaction
Decreased effects with milk or dairy products due to their calcium content.
Action
Description: Sodium phosphate can be used in the management of hypophosphataemia. It also acts as a mild osmotic laxative when given orally as dilute solutions or by the rectal route. Phosphate enemas or concentrated oral solutions are used for bowel cleansing before surgery or endoscopy procedures.
Pharmacokinetics:
Absorption: About 66% of an oral dose is absorbed from the GI tract.
Excretion: Mainly excreted in the urine with the remaining dose via the faeces.
Storage
Oral:
Store at 15-30°C.
Rectal:
Store at 15-30°C.
Disclaimer: This information is independently developed by MIMS based on Sodium phosphate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in